Literature DB >> 16496035

Efficacy of methylphenidate in children with attention-deficit hyperactivity disorder and learning disabilities: a randomized crossover trial.

Natalie Grizenko1, Mamatha Bhat, George Schwartz, Marina Ter-Stepanian, Ridha Joober.   

Abstract

OBJECTIVE: To determine whether children with attention-deficit hyperactivity disorder (ADHD) and learning disabilities respond differently to methylphenidate (MPH) compared with children with ADHD only.
METHODS: We conducted a prospective, double-blind, placebo-controlled, randomized, 2-week crossover trial of MPH, during which response to MPH was assessed. Learning ability was appraised using the Wide Range Achievement Test, Revised (WRAT-R), for English-speaking students and the Test de rendement pour francophones for French-speaking students. The study was conducted at the Douglas Hospital, a McGill University-affiliated teaching hospital in Montréal. Ninety-five children, aged 6-12 years, who met the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV), criteria for ADHD participated in the study, which ran from 2001 to 2004. The outcome measure used was the Consensus Clinical Response, an indicator of the degree of clinical improvement shown when taking MPH.
RESULTS: The proportion of children with learning disabilities who responded to MPH (55%) was significantly smaller (chi(2)1 = 4.5, p = 0.034) than the proportion of children without learning disabilities who responded adequately to MPH (75%). This difference was mainly because of children with mathematics disability being particularly unresponsive to MPH (chi(2)1 = 4.5, p = 0.034). Children with reading disability did not show this pattern of poor response (chi(2)1 = 1.0, p = 0.33).
CONCLUSION: Children with ADHD and comorbid learning disability tended to respond more poorly to MPH. In particular, children with disability in mathematics responded less to MPH than those without disability in mathematics. Additional therapy may be indicated for this group of patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16496035      PMCID: PMC1325066     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  31 in total

Review 1.  Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders.

Authors:  J Biederman; J Newcorn; S Sprich
Journal:  Am J Psychiatry       Date:  1991-05       Impact factor: 18.112

2.  Three parietal circuits for number processing.

Authors:  Stanislas Dehaene; Manuela Piazza; Philippe Pinel; Laurent Cohen
Journal:  Cogn Neuropsychol       Date:  2003-05-01       Impact factor: 2.468

3.  Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity.

Authors:  C K Conners; G Sitarenios; J D Parker; J N Epstein
Journal:  J Abnorm Child Psychol       Date:  1998-08

4.  Neuropsychological analyses of comorbidity between reading disability and attention deficit hyperactivity disorder: in search of the common deficit.

Authors:  Erik G Willcutt; Bruce F Pennington; Richard K Olson; Nomita Chhabildas; Jacqueline Hulslander
Journal:  Dev Neuropsychol       Date:  2005       Impact factor: 2.253

5.  Abnormal executive function in attention deficit hyperactivity disorder: the effect of stimulant medication and age on spatial working memory.

Authors:  R Barnett; P Maruff; A Vance; E S Luk; J Costin; C Wood; C Pantelis
Journal:  Psychol Med       Date:  2001-08       Impact factor: 7.723

Review 6.  Attention-deficit hyperactivity disorder.

Authors:  Joseph Biederman; Stephen V Faraone
Journal:  Lancet       Date:  2005 Jul 16-22       Impact factor: 79.321

7.  Evaluation of individual subjects in the analog classroom setting: I. Examples of graphical and statistical procedures for within-subject ranking of responses to different delivery patterns of methylphenidate.

Authors:  J M Swanson; S B Wigal; D Udrea; M Lerner; D Agler; D Flynn; E Fineberg; M Davies; D Kardatzke; A Ram; S Gupta
Journal:  Psychopharmacol Bull       Date:  1998

8.  Psychostimulant plasma concentration and learning performance.

Authors:  S S Kupietz; B Bartlik; B Angrist; B G Winsberg
Journal:  J Clin Psychopharmacol       Date:  1985-10       Impact factor: 3.153

Review 9.  Perspectives on attention deficit hyperactivity disorder: executive functions, working memory, and language disabilities.

Authors:  Carol Westby; Silvana Watson
Journal:  Semin Speech Lang       Date:  2004-08       Impact factor: 1.761

10.  Treatment effects of methylphenidate on cognitive functioning in children with mental retardation and ADHD.

Authors:  Deborah A Pearson; Cynthia W Santos; Charles D Casat; David M Lane; Susan W Jerger; John D Roache; Katherine A Loveland; David Lachar; Laura P Faria; Christa D Payne; Lynne A Cleveland
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2004-06       Impact factor: 8.829

View more
  16 in total

1.  Predicting methylphenidate response in long-term survivors of childhood cancer: a randomized, double-blind, placebo-controlled, crossover trial.

Authors:  Heather M Conklin; Susan Helton; Jason Ashford; Raymond K Mulhern; Wilburn E Reddick; Ronald Brown; Melanie Bonner; Bruce W Jasper; Shengjie Wu; Xiaoping Xiong; Raja B Khan
Journal:  J Pediatr Psychol       Date:  2009-05-22

2.  Using ADHD Medications to Treat Coexisting ADHD and Reading Disorders: A Systematic Review.

Authors:  Tanya E Froehlich; Jason Fogler; William J Barbaresi; Nada A Elsayed; Steven W Evans; Eugenia Chan
Journal:  Clin Pharmacol Ther       Date:  2018-08-30       Impact factor: 6.875

3.  Genetic evidence for the association of the hypothalamic-pituitary-adrenal (HPA) axis with ADHD and methylphenidate treatment response.

Authors:  Marie-Ève Fortier; Sarojini M Sengupta; Natalie Grizenko; Zia Choudhry; Geeta Thakur; Ridha Joober
Journal:  Neuromolecular Med       Date:  2012-10-10       Impact factor: 3.843

4.  Comparing treatments for children with ADHD and word reading difficulties: A randomized clinical trial.

Authors:  Leanne Tamm; Carolyn A Denton; Jeffery N Epstein; Christopher Schatschneider; Heather Taylor; L Eugene Arnold; Oscar Bukstein; Julia Anixt; Anson Koshy; Nicholas C Newman; Jan Maltinsky; Patricia Brinson; Richard E A Loren; Mary R Prasad; Linda Ewing-Cobbs; Aaron Vaughn
Journal:  J Consult Clin Psychol       Date:  2017-03-23

Review 5.  Low dopamine function in attention deficit/hyperactivity disorder: should genotyping signify early diagnosis in children?

Authors:  Mark S Gold; Kenneth Blum; Marlene Oscar-Berman; Eric R Braverman
Journal:  Postgrad Med       Date:  2014-01       Impact factor: 3.840

6.  Assessing Homework Problems in Children with ADHD: Validation of a Parent-Report Measure and Evaluation of Homework Performance Patterns.

Authors:  Joshua M Langberg; L Eugene Arnold; Amanda M Flowers; Mekibib Altaye; Jeff N Epstein; Brooke S G Molina
Journal:  School Ment Health       Date:  2010-03-01

Review 7.  A Review of the Clinical Utility of Systematic Behavioral Observations in Attention Deficit Hyperactivity Disorder (ADHD).

Authors:  Franziska Minder; Agnieszka Zuberer; Daniel Brandeis; Renate Drechsler
Journal:  Child Psychiatry Hum Dev       Date:  2018-08

8.  Modulating neuronal activity produces specific and long-lasting changes in numerical competence.

Authors:  Roi Cohen Kadosh; Sonja Soskic; Teresa Iuculano; Ryota Kanai; Vincent Walsh
Journal:  Curr Biol       Date:  2010-11-04       Impact factor: 10.834

9.  Atomoxetine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children with ADHD and dyslexia.

Authors:  Calvin R Sumner; Susan Gathercole; Michael Greenbaum; Richard Rubin; David Williams; Millie Hollandbeck; Linda Wietecha
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2009-12-15       Impact factor: 3.033

10.  Therapeutic Response to Methylphenidate in ADHD: Role of Child and Observer Gender.

Authors:  Venkat Bhat; Sarojini M Sengupta; Natalie Grizenko; Ridha Joober
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2020-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.